Dal Chun, MD
Retina Specialist · Vienna, VANPI 1578587135
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,460 of the $12,309 with a category attached, or 68.7%. Regeneron accounts for 78.1% of it on its own, with 15 other manufacturers making up the rest. 2025 is the largest year on record at $10,112, more than ten times the $193 reported in 2019.
Across 109 payments — averaging $112.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$10K
- AbbVie$594
- Astellas Pharma US Inc$377
- Genentech USA, Inc.$369
- Alimera Sciences, Inc.$293
- Regeneron Healthcare Solutions, Inc.$262
- plus $804 from 10 others
Across 1 payment — averaging $17,501 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$18K
What the payments were for
- Consulting fees$8,46069%
- Travel & lodging$8547%
- Food & beverage$2,99524%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 17 | $9,611 |
| AbbVie(2 entities) | 28 | $594 |
| Astellas Pharma US Inc | 11 | $377 |
| Genentech USA, Inc. | 11 | $369 |
| Alimera Sciences, Inc. | 10 | $293 |
| Regeneron Healthcare Solutions, Inc. | 8 | $262 |
| Apellis Pharmaceuticals, Inc. | 5 | $243 |
| Novartis | 5 | $125 |
| Alcon | 1 | $120 |
| Bausch & Lomb Americas Inc. | 4 | $84 |
| Eyepoint US, Inc. | 3 | $62 |
| Kala Pharmaceuticals, Inc. | 2 | $50 |
| ANI Pharmaceuticals, Inc. | 1 | $35 |
| Neurotech Pharmaceuticals, Inc. | 1 | $35 |
| Coherus Oncology, Inc. | 1 | $29 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,309 in reported general payments places this provider in the 85th percentile of 41 retina specialist providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 68 | $2,961 |
| Ketorolac Tromethamine | 94 | $2,718 |
| Brimonidine Tartrate | 35 | $1,159 |
| Latanoprost | 19 | $348 |
| Timolol Maleate | 18 | $254 |
| Ofloxacin | 28 | $234 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 15 | $162 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Vienna
- Jung WooVienna$911
- Nishi GulatiVienna$602
- Jordana FeinManassas$412K
- Joaquin TosiVirginia Beach$48K
- Mohit NandaCharlottesville$31K
- Muge KesenMc Lean$30K
- Anna MackinRoanoke$26K
- Jon AdlebergChesapeake$21K
- Kori ElkinsPortsmouth$9K
- Jiwei ShengFairfax$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.